Shanghai Medicilon Inc.

On June 25 th , the "Resilience and Innovation: 2024 Mithink Summit" hosted by Menet, a subsidiary of the Southern Institute of Medical Economics under the National Medical Products Administration, released the 2023 China Pharmaceutical Industry Top 100 Rankings lists.  Medicilon, with its outstanding R&D capabilities and continuous spirit of innovation, has once again topped the 2023 China CXO (including CDMO) Enterprise Top 20 List.  This is the sixth consecutive year that Medicilon has received this honor. Medicilon's sixth consecutive win of this honor not only represents the industry's authoritative recognition of its comprehensive biopharmaceutical preclinical R&D service platform, but also affirms its contributions to the pharmaceutical research and development field. About the China's Top 100 Pharmaceutical Industry List Series The "China's Top 100 Pharmaceutical Industry List Series" as an authoritative industry list, initiated and h...

On June 27, the 2022 China Pharmaceutical Industry Top 100 Series List was released.  Shanghai Medicilon Inc. was once again shortlisted in the "China CXO Enterprises Top 20 List". Being on the list for five consecutive times is a high affirmation and praise from industry authorities for the comprehensive strength of Medicilon's one-stop  biopharmaceutical preclinical R&D service platform .  It is also the recognition and encouragement of the sustainable development of Medicilon in the future! "China's Top 100 Pharmaceutical Industry List Series" is initiated and hosted by Menet.com.cn, a leading platform for China's pharmaceutical and health information.  It aims to set a benchmark for china pharmaceutical industry enterprises to enhance their comprehensive strength and expand brand effectiveness, demonstrate the excellence of the pharmaceutical brand industry, and guide the steady, rapid and sustainable development of the pharmaceutical and health ...